| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.3 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.047 | 0.3 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |